AI and chip stocks tumble, Meta slides as child-safety trial opens

2 min read
AI and chip stocks tumble, Meta slides as child-safety trial opens
PrimeXBT Editorial Team
Reviewed by PrimeXBT

Topics in article

Stocks moved sharply in Tuesday's midday trading. AI-linked chip and photonics stocks tumbled as investors turned risk-off, Meta Platforms slid as a child-safety trial opened, and Klarna and Baidu dropped on weak results, while Amylyx surged on trial data and Home Depot ticked higher.

Photonics and AI infrastructure names led the session's losses. Coherent and Lumentum tumbled about 12% and 9%, respectively, while Ciena lost around 10% and Teradyne slid 9%. Cloud computing name CoreWeave also fell 9% as investors took a risk-off posture toward the AI build-out trade.

Meta slides as child-safety trial opens

Meta Platforms shares slid 3% after a trial began in which a group of states is suing the company over alleged harm to children and teens. Meta's attorneys have previously said the case could result in damages as high as $1.4 trillion.

Klarna and Baidu drop on weak numbers

Buy-now-pay-later stock Klarna tumbled 21% after guiding Q3 revenue to between $940 million and $980 million, below the $1.11 billion analysts polled by FactSet had expected. The company also cut its 2026 gross merchandise value guidance.

Baidu fell too. Baidu's stock dropped 12% after second-quarter earnings per average diluted share came in at 7.22 yuan, below the FactSet consensus of 9.35 yuan. Revenue of 31.33 billion yuan also missed the 31.78 billion yuan estimate.

Gains among the movers

Not every name fell. Amylyx Pharmaceuticals surged 53% after its avexitide treatment met its primary and secondary endpoints in a Phase 3 trial. Home Depot shares were marginally higher after fiscal second-quarter results beat expectations and the retailer reaffirmed its full-year guidance. Memory chip makers moved lower too: Micron and SK Hynix fell nearly 7% and 8%, while Sandisk dropped more than 8%.

Source: CNBC

Trading involves risk.

Most traded markets

XAU / USD
-0.9% 4,127.61
BRENT
+1.35% 73.620
BTC / USD
+0.7% 63,151.2
EUR / USD
-0.12% 1.14269
USTEC
-0.91% 29,428.7
XAU / USD.24
-0.9% 4,127.61
View all markets

Author

PrimeXBT
Our Editorial Team consists of leading experts with a proven record in the fields of trading, cryptocurrencies, blockchain and finance. We thoroughly research the sources of information in order to provide readers with quality content that serves edu...
Read author’s articles
Alert Triangle Risk Disclaimer
Disclaimer: Some past publications may be outdated. We recommend following our news to stay up to date with the latest information. For any questions, feel free to contact our support team via the chat below.
The content provided here is for informational purposes only. It is not intended as personal investment advice and does not constitute a solicitation or invitation to engage in any financial transactions, investments, or related activities. Past performance is not a reliable indicator of future results.
The financial products offered by the Company are complex and come with a high risk of losing money rapidly due to leverage. These products may not be suitable for all investors. Before engaging, you should consider whether you understand how these leveraged products work and whether you can afford the high risk of losing your money.
The Company does not accept clients from the Restricted Jurisdictions as indicated in our website/ T&C. Some services or products may not be available in your jurisdiction.
The applicable legal entity and its respective products and services depend on the client’s country of residence and the entity with which the client has established a contractual relationship during registration.

Today in markets

Browse Indices News

Register Now

Trading involves risk

Get started in minutes

Our clients love how fast and simple our sign-up is. It takes just a few minutes to get started!

Get Started Get Started
Get started in minutes

Need Help?

Risk Warning:
Trading in leveraged products carries a high level of risk and may not be suitable for all investors.